Reduction of Non-Specific Binding in Assays

ABSTRACT

Methods and compositions are disclosed for reducing non-specific binding in a binding assay for the determination of an analyte in a sample where one of the reagents for conducting the binding assay comprises a solid support comprising a polysaccharide. The method comprises including in an assay medium for conducting the binding assay a soluble compound comprising a protein linked to a polysaccharide. Also disclosed are methods and compositions for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The methods include as reagents a solid support comprising a polysaccharide and a soluble compound comprising a protein linked to a polysaccharide.

BACKGROUND OF THE INVENTION

In the fields of medicine and clinical chemistry, many studies anddeterminations of physiologically reactive species such as cells,proteins, enzymes, cofactors, nucleic acids, substrates, antigens,antibodies, and so forth are carried out using conjugates involvingspecific binding pair members or labels or the like. Various assaytechniques that involve the binding of specific binding pair members areknown. These assay techniques generally also involve a label used in thedetection part of the assay.

Polysaccharides, particularly dextran, have been conjugated to specificbinding pair members, for example, to increase the stability of thespecific binding pair member. In some approaches, a polysaccharide isbound to a surface of a support and a specific binding pair member islinked to the polysaccharide to provide a surface coated withpolysaccharide and having a specific binding pair member attachedthereto. Such supports are employed in assays for analytes. conjugationof specific binding pair members to polysaccharides increases thebulkiness of these molecules, which can enhance their effectiveness inassays involving specific binding pair members by interfering withbinding to complementary specific binding pair members. Additionally,these conjugates, when present on a surface, permit specific binding ofa complementary specific binding pair member to the surface with reducednon-specific binding. The polysaccharide conjugates are employed innumerous types of assays, including homogeneous and heterogeneous assaysand so forth, which are performed on biological samples such as blood,serum, and the like.

There are, however, certain samples such as, for example, serum samples,which produce a positive result independently of the presence or absenceof an analyte in assays in which the aforementioned polysaccharidecoated supports are employed. The likely explanation for this result isthe non-specific binding of components from the sample to one or more ofthe assay reagents particularly the polysaccharide coated support withlinked specific binding pair member. The non-specific binding canincrease the reading of a positive test result, and in some instances,the non-specific binding can produce a positive reading when the analyteis absent, either case providing a misleading assay result.

One approach has been suggested for nonspecific IgG binding to apolymeric solid phase in an immunoassay of a serum sample. The approachinvolves the inclusion of a water-soluble polymer in the liquid phasewhere the water-soluble polymer is formed by polymerization of monomersthat are the same as, or have approximately the same immunologicalbinding affinity as, monomers of the polymer at the solid phase surface.Materials employed as the water soluble polymer includedpoly(styrene-alt-maleic acid) and poly(acrylic acid), which demonstratedsuperiority over poly(methacrylic acid) and dextran and a number ofother materials.

There remains a need for agents for blocking non-specific binding inassays involving polysaccharide conjugates linked to a support.

SUMMARY OF THE INVENTION

One embodiment of the present invention is a method for reducingnon-specific binding in a binding assay for the determination of ananalyte in a sample wherein one of the reagents for conducting thebinding assay comprises a solid support comprising a polysaccharide. Themethod comprises including in an assay medium for conducting the bindingassay a soluble compound comprising a protein linked to apolysaccharide.

Another embodiment of the present invention is a method for determiningthe presence and/or amount of an analyte in a sample suspected ofcontaining the analyte. A combination is provided that comprises thesample, a soluble compound comprising a protein linked to apolysaccharide, and reagents for detecting the analyte. At least one ofthe reagents for detecting the analyte is a support comprising apolysaccharide. The combination is incubated under conditions forbinding of the analyte to one or more of the reagents. The presenceand/or amount of binding of the analyte to one or more of the reagentsis determined where the presence and/or amount of the binding is relatedto the presence and/or amount of the analyte in the sample.

Another embodiment of the present invention is a composition comprisinga polysaccharide linked to a protein, wherein the linkage between thepolysaccharide and the protein has substantially the same structure asthe linkage used for linking the specific binding pair members to thesurface of a solid phase reagent of an assay.

Another embodiment of the present invention is a protein-polysaccharideconjugate comprising repeating monosaccharide units and are of theformula:

wherein one of the A's is a bond to the C1 glycosidic carbon (asindicated in the above formula) of another of the units, n is an integerof about 3 to about 50,000, the other A's are independently selectedfrom the group consisting of protein molecules, hydrogen, groupsimparting water solubility, or crystallinity reducing substituents, andL is a bond or a linking group, and the ratio of protein molecules tomonosaccharide molecules is in the range of about 1:2 to about 1:100.

In some embodiments, when L is a linking group and A is a protein, L-Ahas the formula:—CH₂(CH₂)_(m)CR′—NR-proteinwherein m is an integer of 0 to about 5, R and R′ are independentlyselected from the group consisting of hydrogen, lower alkyl, and aryl,or R and R′ may be taken together to form a double bond.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

As mentioned above, in one aspect a method is provided for reducingnon-specific binding in a binding assay for the determination of ananalyte in a sample wherein one of the reagents for conducting thebinding assay comprises a solid support comprising a polysaccharide. Themethod comprises including in an assay medium for conducting the bindingassay a soluble compound comprising a protein linked to apolysaccharide.

Non-specific binding, in general, means non-covalent binding betweenmolecules that is relatively independent of specific surface structures.Non-specific binding is distinguished from specific binding, whichinvolves the specific recognition of one of two different molecules forthe other compared to substantially less recognition of other molecules.Non-specific binding may result from several factors includinghydrophobic interactions between molecules, electrostatic or ionexchange interactions between molecules, species-specific interactionsbetween molecules (e.g., human anti-mouse antibody, mouse anti-sheepantibody, and the like), and so forth. The nature of the molecule ormolecules that result in non-specific binding in assays is dependent onthe nature of the sample, the assay milieu, the solid phase reagentsurface, and so forth. For the most part the non-specific bindingmolecules are protein materials such as, for example, non-specificimmunoglobulins, immunoglobulins having specificity to molecules otherthan the analyte of the assay, complement cascade proteins, clottingcascade proteins, and the like. The sample may be biological tissue,which includes excised tissue from an organ or other body part of a hostand body fluids, for example, whole blood plasma, serum, urine, saliva,semen, stool, sputum, cerebral spinal fluid, tears, mucus, and the like.In many instances, the sample is plasma or serum.

The binding assay generally involves specific binding between molecules.The molecules may be referred to as members of a specific binding pair(“sbp”), which means one of two different molecules, having an area onthe surface or in a cavity, which specifically binds to and is therebydefined as complementary with a particular spatial and polarorganization of the other molecule. The members of the specific bindingpair may also be referred to as ligand and receptor (antiligand). Thesewill usually be members of an immunological pair such asantigen-antibody, although other specific binding pairs such asbiotin-avidin, hormones-hormone receptors, nucleic acid duplexes,IgG-protein A, polynucleotide pairs such as DNA-DNA, DNA-RNA, and thelike are not immunological pairs but are included in the definition ofsbp member. Binding assays are discussed in more detail below.

The reagents for conducting the binding assay usually include one ormore sbp members, which may or may not be bound to other moleculesdepending on the nature of a particular assay in which the reagents areemployed. One or more specific binding pairs may be utilized dependingon the nature of the assay. The sbp member may or may not be bound to asupport, a member of a signal producing system such as a label, an sbpmember from a different specific binding pair, and so forth.Accordingly, the reagents for conducting an assay may include additionalsbp members, ancillary reagents such as an ancillary enzyme substrate,signal producing system members, buffers, blocking agents for otherforms of non-specific binding, and so forth. The reagents utilized forconducting a binding assay depend on the nature of the assay to beconducted and are discussed in detail below with respect to variousassay embodiments. One or more particulate reagents may be employed inan assay depending on the nature of the assay.

One of the reagents for conducting a binding assay is a supportcomprising a polysaccharide, which is a carbohydrate containing three ormore monosaccharide units. The polysaccharide can be straight-chained orbranched. The molecular weight (in Daltons) of the polysaccharide isabout 10,000 to about 5 million or more, and in some instances 10,000 toabout 1 million or more, and in some instances about 10,000 to about500,000, and in some instances about 30,000 to about 350,000.

Examples of polysaccharides by way of illustration and not limitationare dextran, dextran derivatives, cyclodextrin, cellulose derivatives,agarose, gums, starch, glycogen, polyribose, amylose, and the like. Amonosaccharide is a carbohydrate that cannot be hydrolyzed into simplercompounds such as an aldehyde alcohol or a ketone alcohol, e.g., ahexose or a pentose. Dextran is a polysaccharide consisting of linear1-6 linked (98%) glucose units and may be referred to as a polymerizedglucose. Dextran derivatives are dextran modified by cross-linking,degradation, functionalization, or the like, such as, for example,modification of one ore more hydroxyl groups by linking to anothermoiety or by modification to a different functional group such as, forexample, carboxyl, sulfate, sulfite, sulfone, amide, sulfonamide,halomethylcarbonyl, epoxide, amino, aldehyde, active ester, maleimide,and the like. Where the polysaccharide is not water soluble, themodification may include one or more groups or functionalities impartingwater solubility as discussed below.

The nature of the polysaccharide-support reagent is primarily dependenton the nature of the binding assay. In many instances the polysaccharideis non-diffusively bound to the surface of a support. Polysaccharide maybe non-diffusively bound to the surface of a support either covalently(by direct bond to the polysaccharide or by a linking group) ornon-covalently (by adsorption, precipitation (e.g. agarose), and thelike) as long as the polysaccharide remains substantially bound to thesurface under the conditions of an assay or other conditions to whichsuch supports are subjected. Approaches for coating a surface of asupport with a polysaccharide are known in the art. For example,approaches are discussed in Immunological Diagnostic Reagents, U.S. Pat.No. 4,264,766, Ernst A. Fischer, Apr. 28, 1981, the relevant portions ofwhich are incorporated herein by reference.

The support is generally a solid phase, which is usually a porous ornon-porous water insoluble material that can have any one of a number ofshapes, such as strip, rod, plate, well, particle or bead, and so forth.A wide variety of suitable supports are disclosed in Ullman, et al.,U.S. Pat. No. 5,185,243, columns 10-11, which is incorporated herein byreference.

The surface can be hydrophilic or capable of being rendered hydrophilicand includes inorganic powders such as silica, magnesium sulfate, andalumina; natural polymeric materials, particularly cellulosic materialsand materials derived from cellulose, such as fiber containing papers,e.g., filter paper, chromatographic paper, glass fiber paper, etc.;synthetic or modified naturally occurring polymers, such asnitrocellulose, cellulose acetate, poly(vinyl chloride), polyacrylamide,cross linked dextran, agarose, polyacrylate, polyethylene,polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate,poly(ethylene terephthalate), nylon, poly(vinyl butyrate), etc.; eitherused by themselves or in conjunction with other materials; glass such ase.g., glass available as Bioglass, ceramics, metals, and the like.Natural or synthetic assemblies such as liposomes, phospholipidvesicles, and cells can also be employed. The support may include moldedparts such as, for example, wells of a microtiter well plate, paddles,spheres, and so forth.

Particles may be uniform or non-uniform in shape and may be microscopicor macroscopic in size. The particles may be of at least about 20 mm andnot more than about 20 microns, and in some instances, at least about 40nm and less than about 10 microns, and in some instances from about 0.10to 2.0 microns diameter. The particle may have any density, butpreferably of a density approximating water, generally from about 0.7 toabout 1.5 g/ml. The particles may or may not have a charge, and whenthey are charged, they are preferably negative. The particles may besolid (e.g., comprised of organic and inorganic polymers or latex), oildroplets (e.g., hydrocarbon, fluorocarbon, silicon fluid), or vesicles(e.g., synthetic such as phospholipid or natural such as cells andorganelles).

The solid particles are normally polymers, either addition orcondensation polymers, which are readily dispersible in the assaymedium. The solid particles are also adsorptive or functionalizable soas to bind or attach at their surface, either directly or indirectly, apolysaccharide, a polysaccharide-sbp member conjugate, or the like, andin some instances to incorporate within their volume a reactive reagent.The particles may be non-magnetic or magnetic.

The solid particles can be comprised of polystyrene, polyacrylamide,homopolymers and copolymers of derivatives of acrylate and methacrylate,particularly esters and amides, silicones and the like. Oil droplets arewater-immiscible fluid particles comprised of a lipophilic compoundcoated and stabilized with an emulsifier that is an amphiphilic moleculesuch as, for example, phospholipids, sphingomyelin, albumin and the likethat exist as a suspension in an aqueous solution, i.e. an emulsion.Liposomes are microvesicles comprised of one or more lipid bilayershaving approximately spherical shape and one of the preferred materialsfor use in the present invention.

Latex particles are a particulate water suspendable, water insolublepolymeric material usually having particle dimensions of 20 nm to about2000 nm, in some instances about 100 to about 1000 nm in diameter. Thelatex may be a substitute polyethylene such as polystyrene-butadiene,polyacrylamide polystyrene, polystyrene with amino groups, substitutedpoly-acrylic acid, substituted polymethacrylic acid,acrylnitrile-butadiene, styrene copolymers, polyvinyl acetate-acrylate,vinyl-chloride acrylate copolymers, and the like. Non-crosslinkedpolymers of styrene and carboxylated styrene or styrene functionalizedwith other active groups such as amino, hydroxyl, halo and the like arepreferred. In some instances, copolymers of substituted styrenes withdienes such as butadiene will be used.

As mentioned above, in order to reduce non-specific binding in a bindingassay for the determination of an analyte in a sample wherein one of thereagents for conducting the binding assay comprises a solid supportcomprising a polysaccharide, a soluble compound comprising a proteinlinked to a polysaccharide is present in the assay medium. Thepolysaccharide of the soluble compound may be selected from thepolysaccharides mentioned above and may be the same as, or differentfrom, the polysaccharide on the support. When the polysaccharides aredifferent, they may differ by being derived from different derivativesof the same polysaccharide or they may differ by comprising differentmonosaccharide units in the polymeric chain. When different, thepolysaccharide of the soluble compound may differ by being chemicallystructurally similar but of differing molecular weights. The molecularweight (in Daltons) of the polysaccharide of the soluble compound shouldbe about 10,000 to about 1,000,000 or about 40,000 to about 500,000 orthe like. In other situations where the polysaccharides are different,the polysaccharide of the soluble conjugate should have thecharacteristic of being capable of binding to the same binding site ofthe interfering binder found in the discrepant samples that binds to thepolysaccharide on the support.

The polysaccharide-protein conjugate is soluble in the assay medium inwhich it is employed. The solubility of the conjugate is dependent onthe nature of the assay medium, the temperature of the assay medium,factors that determine the presence of crosslinking of the conjugatesuch as the starting molecular weight of the protein and thepolysaccharide, as well as the stoichiometry of the polysaccharide andthe protein used in the synthesis of the conjugate, and so forth. Inmany instances, the assay medium is an aqueous medium, usually anaqueous buffered medium. The aqueous medium may be solely water or mayinclude from about 0.01 to about 80 volume percent, and in someinstances, about 0.1 to about 40 volume percent, of a cosolvent. Thecosolvent may be an oxygenated hydrocarbon such as, for example, analcohol, an ether, an amide, a ketone, and the like. Lower alkylalcohols such as, for example, methanol, ethanol, propanol and so forthmay be employed. The pH for the medium is generally a moderate pH and isthe range of about 4 to about 11, or in the range of about 5 to about10, or in the range of about 6.5 to about 9.5. The pH will usually be acompromise between optimum binding of the binding members of anyspecific binding pairs, the pH optimum for other reagents of the assaysuch as embers of the signal producing system, and so forth.

Various buffers may be used to achieve the desired pH and maintain thepH during the assay. Illustrative buffers include borate, phosphate,carbonate, tris, barbital and the like. Various ancillary materials maybe employed in the assay medium. For example, in addition to buffers themedium may comprise stabilizers for the medium and for the reagentsemployed. In some instances, in addition to these additives, proteinsmay be included, such as albumins; polyanions such as dextran sulfate;surfactants, particularly non-ionic surfactants; binding enhancers,e.g., polyalkylene glycols; or the like. Some additives, such as someother water soluble polymers and some salts at high concentration mayrender the conjugates insoluble due to incompatibility, so their usewould be precluded with the polysaccharide-protein conjugates.

The practical limit of concentration of the polysaccharide-proteinconjugate is determined by the viscosity of the solution of theconjugate in buffer, which will, in turn, be affected by the molecularweight of the conjugate. The practical viscosity limit for conjugates ofmolecular weight 10 million is in the range of about 1 to about 5%.

In many embodiments where the assay medium is aqueous, thepolysaccharide-protein conjugate is water soluble. The term“water-soluble” is used herein to refer to freely soluble in water atessentially all proportions as well as those of only limited solubility,i.e., limited to the extent mentioned above. Conjugates of limited watersolubility can be employed, where appropriate, at concentrations belowtheir solubility limits.

If the components of the conjugate are not already water soluble so thatthe resulting conjugate is water soluble, one or both of the componentsmay be functionalized to impart water solubility to the conjugate byincorporating one or more groups or functionalities that imparthydrophilicity. One of skill in the art may readily determine theappropriate substitution, taking into consideration the desired effectand/or materials that are readily available. Such a group orfunctionality is in many instances a hydrophilic functionality, whichincreases wettability of solids with water and the solubility in waterof compounds to which it is bound. Such functional group orfunctionality can be a substituent having 1 to 50 or more atoms and caninclude a group having a sulfonate, sulfate, phosphate, amidine,phosphonate, carboxylate, hydroxyl particularly polyols, amine, ether,amide, and the like. Illustrative functional groups are carboxyalkyl,sulfonoxyalkyl, CONHOCH₂COOH, SO₂NHCH₂COOH, SO₃H, CONHCH₂CH₂SO₃H, PO₃H₂,OPO₃H₂, hydroxyl, carboxyl, ketone, and combinations thereof. Most ofthe above functionalities can also be utilized as attaching groups,which permit attachment of the polysaccharide to a protein or viceversa.

It should be noted that the polysaccharide of the soluble compound andthe polysaccharide on the support are sometimes referred to herein andin the accompanying claims as first polysaccharide and secondpolysaccharide. This designation is made to distinguish betweenpolysaccharide on the support and polysaccharide of the solublecompound, which may be different. The designation is purely arbitraryand is not meant to convey any order of preference, addition, or thelike to the polysaccharide(s) employed.

The protein component of the soluble compound may be any protein that,when part of the soluble compound and used as discussed herein, willresult in a reduction of non-specific binding in an assay. The nature ofthe protein employed is dependent on the nature of the sample to beanalyzed, the molecular weight of the protein, its chemical reactivity,its solubility properties, and so forth. In most instances, the proteinof the soluble compound is a none that will not interfere with an assayfor an analyte. Therefore, the protein should not be specific bindingpair member for any reagent or analyte of an assay or any component of asample to be analyzed. The protein may be of animal (including insect,fish, fowl and so forth) or vegetable origin. Suitable animal proteinsinclude proteins from blood serum, plasma, digested collagen, and thelike. Suitable vegetable proteins include pumpkin seed globulin, and thelike. Blood proteins include, by way of illustration and not limitation,gamma globulins, such as goat, bovine, sheep, and mouse gamma globulin;albumins such as bovine serum albumin, human serum albumin, ovalbumin,and so forth. Examples of other proteins include casein; gelatins suchas enzymatic gelatin hydrolysate, fish gelatin, and fish skin gelatin;and the like.

In the conjugate, the number of protein molecules per polysaccharide isdependent upon concentrations of activated species during conjugation,degree of activation of species, size and shape of polysaccharidederivative, size and shape of the protein, and so forth. One skilled inthe art may readily determine the appropriate substitution, taking intoconsideration the desired effect and/or materials that are readilyavailable. The ratio of polysaccharide molecules to protein molecules inthe conjugate is generally about 5 to about 1, about 4 to about 1, about3 to about 1, about 2 to about 1, about 1 to about 1, about 1 to about2, about 1 to about 3, about 1 to about 4, about 1 to about 5, and soforth. In general, the ratio will depend on the nature of thepolysaccharide such as, e.g., the chemical composition, molecularweight, etc., and on the nature of the protein such as, e.g., chemicalcomposition, molecular weight, etc., and in some instances may bedetermined empirically.

A wide variety of techniques may be employed to link the polysaccharideand the protein to form the soluble compound. In one approach, apolysaccharide is treated by known oxidative methods (e.g., activationwith periodate, perbromate, and the like) to yield an oxidative formwherein at least a portion of the saccharide monomeric units areoxidized to present aldehyde groups. The oxidized polysaccharide soformed is then reacted with a protein, which through primary aminegroups reacts with the aldehyde groups of the oxidized polysaccharideand covalently binds to the polysaccharide through Schiff base linkages.This type of reaction is also referred to as reductive amination.

Another example involves an amino derivatized polysaccharide or acarboxylmethyl polysaccharide, which reacts with a protein to form anamide product. For example, aminodextran or carboxymethyldextran haveusually been utilized for forming conjugates to specific binding pairmembers. Coupling the dextran to a protein, for example, can then becarried out through formation of an amide.

A variety of antibody-aminodextran conjugates are described in U.S. Pat.No. 5,527,713 and U.S. Pat. No. 5,658,741. Such techniques may beemployed to link proteins to polysaccharides in general. Recently,polymeric carriers containing the divinyl sulfone moiety for covalentattachment of protein and other molecular species were described inEuropean Patent No. 0 594 772 B1.

Aminodextran can be prepared by methods described in U.S. Pat. No.5,466,609 and U.S. Pat. No. 5,527,713, by periodate oxidation of dextranfollowed by reaction with 1,3-propanediamine. Of course, the particularmethod of making the aminodextrans is not limited to such techniques andit is envisioned that any technique for making such aminodextrans arewell within the knowledge of those of skill in the art. For example, oneof skill in the art may readily substitute a diaminoalkane having two tosix carbons for 1,3-propanediamine described in the examples.Preferably, the aminodextran is 5X-Amdex or 1X-Amdex, and mostpreferably 5X-Amdex.

The linking group may be a chain of from 1 to about 30 or more atoms,from about 1 to about 20 atoms, about 1 to about 10 atoms, eachindependently selected from the group normally consisting of carbon,oxygen, sulfur, nitrogen, and phosphorous, usually carbon and oxygen.The number of heteroatoms in the linking group normally ranges fromabout 0 to about 8, from about 1 to about 6, about 2 to about 4. Thenumber of atoms in the chain is determined by counting the number ofatoms other than hydrogen or other monovalent atoms along the shortestroute between the substructures being connected. The atoms of thelinking group may be substituted with atoms other than hydrogen such ascarbon, oxygen and so forth in the form, e.g., of alkyl, aryl, aralkyl,hydroxyl, alkoxy, aryloxy, aralkoxy, and the like. As a general rule,the length of a particular linking group can be selected arbitrarily toprovide for convenience of synthesis with the proviso that there beminimal interference caused by the linking group with the ability of thelinked molecules to perform their function related to the assay inquestion.

The linking group may be aliphatic or aromatic. When heteroatoms arepresent, oxygen will normally be present as oxy or oxo, bonded tocarbon, sulfur, nitrogen or phosphorous; sulfur will be present asthioether or thiono; nitrogen will normally be present as nitro, nitrosoor amino, normally bonded to carbon, oxygen, sulfur or phosphorous;phosphorous will be bonded to carbon, sulfur, oxygen or nitrogen,usually as phosphonate and phosphate mono- or diester. Functionalitiespresent in the linking group may include esters, thioesters, amides,thioamides, ethers, ureas, thioureas, guanidines, azo groups,thioethers, carboxylate and so forth.

Examples, by way of illustration and not limitation, of various linkinggroups that find use in the present invention are found in U.S. Pat. No.3,817,837, particularly at column 30, line 69, to column 36, line 10,which disclosure is incorporated herein by reference in its entirety.Various linking groups and linking functionalities are disclosed inCautrecasas, J. Biol. Chem. (1970) 245:3059. Examples of commerciallyavailable cross-linking reagents are disclosed in the pierce Catalog andHandbook, Life Science and Analytical Research Products, Pierce ChemicalCompany, Rockford, Ill. 1994/1995.

The compounds according to the invention can be purified withconventional methods, for example, chromatography, filtration includingmicrofiltration, ultrafiltration, diafiltration, etc., precipitation,dialysis, and the like.

The soluble protein-polysaccharide conjugate usually carries a neutralcharge or a negative charge. If the charge of the solubleprotein-polysaccharide conjugate is not neutral, it is desirable thatthe soluble compound have the same charge as the support reagentcomprising a polysaccharide. The support reagent comprising apolysaccharide usually has a negative charge and, thus, the solubleprotein-polysaccharide conjugate should have a negative or neutralcharge.

One or more of the reagents for conducting an assay, other than thesoluble compound or a support comprising a polysaccharide, may includean additional support reagent, which may or may not comprise apolysaccharide. If the additional support reagent comprises apolysaccharide, the polysaccharide may be the same as or different fromthe polysaccharide of the other support reagent or of the solublecompound. For example, two or more sets of particle reagents may beemployed in an assay depending on the assay format. One or more of theparticle reagents may comprise a polysaccharide. One particle reagentmay be coated with a polysaccharide, which is linked to one sbp memberof a specific binding pair, and another particle reagent may be coatedwith a polysaccharide, which is linked to another sbp member from adifferent specific binding pair. It should be obvious to one skilled inthe art that numerous assay formats are possible where a solubleprotein-polysaccharide conjugate may be employed to avoid non-specificbinding in an assay.

It is usually desirable that the affinity binding behavior of thesoluble compound is greater than the affinity binding behavior of thepolysaccharide on the support. The phrase “affinity binding behavior”relates to affinity strength and specificity in the types ofinteractions that typically constitute immunological or affinity bindingsuch as, for example, antigen-antibody-type binding. In some embodimentsthe affinity binding behavior of the soluble compound is greater thatthe affinity binding behavior of the polysaccharide on the support by atleast about 2 times, at least about 3 times, at least about 4 times, atleast about 5 times, at least about 10 times, at least about 15 times,at least about 20 times, at least about 30 times, at least about 40times, at least about 50 times, at least about 100 times, at least about150 times, at least about 200 times, at least about 250 times at leastabout 300 times, or more.

The amount of soluble protein-polysaccharide compound employed isusually an amount sufficient to reduce significantly or eliminateinterference from non-specific binding in specific binding assays. Asignificant reduction of interference from non-specific binding isachieved when an assay response is greater than that achieved in theabsence of the soluble protein-polysaccharide conjugate and whether ornot in the presence of components of the conjugate separate from theconjugate such as protein alone or polysaccharide alone or a combinationof separate protein and separate polysaccharide and whether or not othermaterials for reducing interference are present. The amount of solublecompound used in any particular assay is usually determined empirically.Usually, the soluble compound is employed in an excess amount. Theamount of soluble compound may be about 0.1 to about 5 mg/mL, in someinstances about 0.5 to about 2 mg/mL, in the assay medium. However, theabove amounts are by way of illustration and not limitation. Amountsoutside the above ranges may be employed in certain circumstances aslong as the amount is sufficient to reduce significantly or eliminateinterference from non-specific binding in specific binding assays.

Specific Embodiments of Protein-Polysaccharide Conjugates

Specific embodiments of exemplary soluble compounds are discussed nextby way of illustration and not limitation.

In some embodiments the protein-polysaccharide conjugates compriserepeating monosaccharide units and are of the formula:

wherein one of the A's is a bond to the C1 glycosidic carbon (asindicated in the above formula) of another of the units, n is an integerof about 3 to about 50,000, or about 25 to about 10,000, or about 50 toabout 1,000, L is a bond or a linking group as defined above and theother A's are independently selected from the group consisting ofprotein molecules, hydrogen, groups imparting water solubility, orcrystallinity reducing substituents.

The term “crystallinity reducing substituents” refers to groups orfunctionalities that reduce or eliminate crystallinity from the parentbackbone of the polysaccharide thereby increasing the solubility of thepolysaccharide or subsequent conjugate. Crystallinity reducingsubstituents include, for example, carboxymethyl substituents (e.g., oncellulose and the like), methyl, hydroxyethyl, and the like.

The number of A's that are protein molecules is dependent on factorssuch as the size of the protein molecule and so forth. In someembodiments the ratio of protein molecules to monosaccharide moleculesis in the range of about 1:2 to about 1:100, or about 1:3 to about 1:95,or about 1:4 to about 1:90, or about 1:5 to about 1:85, or about 1:6 toabout 1:80, or about 1:7 to about 1:75, or about 1:8 to about 1:70, orabout 1:9 to about 1:65, or about 1:10 to about 1:60, or about 1:15 toabout 1:55, or about 1:20 to about 1:50, or about 1:25 to about 1:45, orabout 1:30 to about 1:40. In some embodiments one of the A's is aprotein molecule for at least every two monosaccharide molecules, for atleast about every three monosaccharide molecules, for at least aboutevery four monosaccharide molecules, for at least about every fivemonosaccharide molecules, for at least about every six monosaccharidemolecules, for at least about every seven monosaccharide molecules, forat least about every eight monosaccharide molecules, for at least aboutevery nine monosaccharide molecules, for at least about every tenmonosaccharide molecules, for at least about every fifteenmonosaccharide molecules, for at least about every twenty monosaccharidemolecules, for at least about every twenty five monosaccharidemolecules, for at least about every thirty monosaccharide molecules, forat least about every thirty five monosaccharide molecules, for at leastabout every forty monosaccharide molecules, for at least about everyforty five monosaccharide molecules, for at least about every fiftymonosaccharide molecules, and so forth.

In some embodiments, when A is a protein, L is a linking group of theformula, which includes the protein moiety:—CH₂(CH₂)_(m)CHR′—NR-proteinwherein R and R′ are independently selected from the group consisting ofhydrogen, lower alkyl, aryl, and the like or R and R′ may be takentogether to form a double bond between CH and N (i.e.,—CH₂(CH₂)_(m)CH═N—) and wherein m is an integer of 0 to about 5, about 1to about 5, about 1, to about 4, about 1 to about 3, about 1 to about 2,and wherein the nitrogen is from an amino acid of the protein.

In some embodiments, when A is a protein, L is a linking group of theformula:—CH₂(CH₂)_(m)—NR—CH₂(CH₂)_(p)CH₂—wherein m and p are independently integers of 0 to about 5, about 1 toabout 5, about 1, to about 4, about 1 to about 3, about 1 to about 2,and R is selected from the group consisting of hydrogen, lower alkyl,aryl, and the like. In some embodiments the linking group L is formed bythe reaction of a linking group on the polysaccharide comprising aterminal aldehyde group and a nitrogen group of the protein moleculesuch as, for example, a nitrogen group of an amino acid residue of theprotein molecule. Accordingly, the —NR—CH₂(CH₂)_(p)CH₂— portion of theabove linking group may come from an amino acid residue of the proteinsuch as, for example, a lysine (where the linking group comprises—NR—CH₂(CH₂)₂CH₂—CH(COOH)NH— and the polysaccharide conjugate ispolysaccharide-CH₂(CH₂)₃CH₂—NR—CH₂(CH₂)₂CH₂—CH(COOH)NH-protein, and thelike. In some embodiments the protein molecules are selected from thegroup consisting of albumins and gamma-globulins.

In some embodiments, when A is a protein, L is a linking group of theformula:—CH₂(CH₂)_(m)CH₂—NR—CHR′(CH₂)_(p)CO—wherein m and p are independently integers of 0 to about 5, about 1 toabout 5, about 1, to about 4, about 1 to about 3, about 1 to about 2 andR and R′ are independently selected from the group consisting ofhydrogen, lower alkyl, aryl, and the like. In some embodiments thelinking group L is formed by the reaction of a linking group on thepolysaccharide comprising a terminal aldehyde group and a nitrogen groupof the protein molecule such as, for example, a nitrogen group of anamino acid residue of the protein molecule. Accordingly, the—NR—CHR′(CH₂)_(p)CO— portion of the above linking group may come from anamino acid residue of the protein such as, for example, the N-terminalamino acid of the protein, and the like. In some embodiments the proteinmolecules are selected from the group consisting of albumins andgamma-globulins.

In some embodiments the protein-polysaccharide conjugates areprotein-dextran conjugates of the formula:

wherein one or more of the n′ monosaccharide units have the formula:

protein-substituted monosaccharideand wherein n′ is an integer of about 3,000 to about 60,000, m is asdefined above, R is as defined above, protein is, for example a gammaglobulin or an albumin, and wherein the protein —NR-protein may be—NR—CH₂(CH₂)_(p)CH₂-protein wherein p is a defined above and wherein the—NR—CH₂(CH₂)_(p)CH₂— portion of the above linking group may come from anamino acid residue of the protein such as, for example, a lysine, andthe like, or wherein the —NR-protein may be —NR—CHR′(CH₂)_(p)CO-proteinwherein the —NR—CHR′(CH₂)_(p)CO— portion of the above linking group maycome from an amino acid residue of the protein such as, for example, theN-terminal amino acid of the protein, and the like. The number ofprotein-substituted monosaccharide units is about 20 to about 500 for n′of about 3,000 to about 60,000 (corresponding to a molecular weight ofabout 10 million), and the like, by way of example and not limitation.

In a specific embodiment of the above, m is 4, the —NR-protein is—NR—CH₂(CH₂)_(p)CH₂-protein wherein p is 2. In another specificembodiment of the above, —NR-protein is—NR—CH₂(CH₂)₂CH₂—C(COOH)NH-protein.

The above protein-dextran conjugates may be synthesized from thecorresponding dextran aldehyde, which reacts with an amino group on theprotein such as, for example, an amino group of an N-terminal aminoacid, e.g., a lysine, of the protein.

dextran aldehyde portion of polysaccharide above

In an exemplary approach to the synthesis of dextran aldehyde by way ofillustration and not limitation, dextran is combined in an aqueousmedium under basic conditions with an appropriate dioxolane such as, forexample, 2-(4-halobutyl)-1,3-dioxolane wherein halo is chloro, boromo oriodo. Basic conditions may be achieved by inclusion in the aqueousmedium of a base such as, for example, sodium hydroxide, potassiumhydroxide, or the like. The pH of the basic medium is greater than about14. The reaction is carried out at elevated temperature of about 30° C.to about 100° C., or about 50° C. to about 90° C. for a time period ofabout 6 to about 48 hours, or about 12 to about 24 hours. Then, water isadded and the mixture is cooled to room temperature. The pH is adjustedto about 5 to about 7, or about 6 to about 6.5, by addition of an acidsuch as, for example, a mineral acid, e.g., hydrochloric acid, and thelike, or an organic acid, e.g., acetic acid, and the like. The resultingdextran aldehyde product may be subjected to various techniques forisolation and purification as discussed above.

Then, the dextran aldehyde is reacted with an amine of the protein.Generally, this reaction is carried out under mildly acidic conditionsin the presence of a reducing agent such as cyanoborohydride or thelike. The pH of the reaction medium containing the reactants should below enough to permit an appreciable number of the amine groups to beprotonated but not so low as to result in an insufficient amount of thefree amine compounds. The pH is usually about 4 to about 7, or about 5to about 6.5, or about 5.5 to about 6. The time period for the reactionis usually about 10 to 20 hours, preferably, about 14 to 18. Thetemperature of the reaction mixture is generally about 15 to 30° C.,usually, about 20 to 25° C.

It is often desirable to quench any aldehyde functionalities that havenot reacted with polypeptide. To this end, the conjugate produced aboveis treated with a suitable quenching reagent that will form a stableproduct with the remaining free aldehyde groups. Such a quenching agentcan be, for example, hydroxyl amine, semicarbazide, phenylhydrazine,hydrazine, sodium cyanide, carboxymethoxyamine, and the like. Theresulting product is purified by conventional means such as, forexample, ultrafiltration, precipitation, dialysis and so forth.

Other approaches for preparing the above conjugates include thefollowing:

In one approach the polysaccharide is reacted with a suitable alkylatingagent such as, for example, epichlorohydrin or divinylsulfone, tointroduce epoxide or vinylsulfone amine reactive functionality.

In another approach an amine reactive functionality can be introducedthrough oxidation of the polysaccharide with periodate to generatealdehyde groups that are amine reactive.

In some instances it may be desirable to form the protein-polysaccharideconjugate in situ. This may be accomplished, in the case of dextran, forexample, by adding dextran aldehyde to a medium containing the protein.Such a medium may be, for example, a serum sample that is to beanalyzed. The protein for forming the conjugate may be present in theserum sample or it may be added prior to adding the dextran aldehyde.The soluble protein-polysaccharide conjugate formed in situ may beutilized where a somewhat lower blocking of sample interference may betolerated in an assay. For the most part, soluble protein-polysaccharideconjugates formed as a separate entity and then added to the sample tobe analyzed provide better protection against interfering substances andare better utilized for samples that are more challenging with respectto protection against such interfering substances.

As mentioned above, another embodiment of the invention is a compositioncomprising a polysaccharide linked to a protein, wherein the linkagebetween the polysaccharide and the protein has substantially the samestructure as the linkage used for linking a specific binding pair memberto a polysaccharide on the surface of a solid phase reagent of an assay.In accordance with this embodiment, the linkage has substantially thesame structure if the chemical structure of the linkage is substantiallythe same. This linkage may be a bond or a linking group as discussedabove. The linking group is substantially the same, for example, whenthere is a homologous relationship between the linking groups where thedifference due to homology is no more than 3 carbon atoms, no more than2 carbon atoms, no more than 1 carbon atom. If the linking groupcomprises one or more functional groups, the linking groups aresubstantially the same where the functional groups of one linking groupare the same as the functional groups of the other linking group.

Examples of Assays Employing the Water Soluble Compounds

As mentioned above, the soluble protein-polysaccharide compounds orconjugates discussed above can be utilized in binding assays foranalytes. The assay methods usually involve a sample suspected ofcontaining an analyte, which is combined in an assay medium withreagents for carrying out the assay. Such reagents include a support orsolid phase that comprises a polysaccharide and may further comprise ansbp member. Other assay reagents can include a binding partner for theanalyte if the sbp member on the solid support is not a binding partnerfor the analyte, analyte analogs, other solid supports to which one ofthe above reagents is bound, binding partners for sbp members, and soforth. One or more of the reagents may be part of a signal producingsystem where at least one of the reagents can be labeled. The reagentsare chosen such that a signal is obtained from a label in relation tothe presence or amount of analyte in the sample. The assay can beperformed either without separation (homogeneous) or with separation(heterogeneous) of any of the assay compounds or products. Since solidsupports are utilized, the assay is usually heterogeneous althoughhomogeneous formats using such reagents are known.

Heterogeneous assays usually involve one or more separation steps andcan be competitive or non-competitive. A variety of competitive andnon-competitive heterogeneous assay formats are disclosed in Davalian,et al., U.S. Pat. No. 5,089,390, column 14, line 25 to column 15, line9, incorporated herein by reference. In a typical competitiveheterogeneous assay a support having an antibody for analyte boundthereto by means of a polysaccharide is contacted with a mediumcontaining the sample and analyte analog conjugated to a detectablelabel such as an enzyme (the “conjugate”). Analyte in the samplecompetes with the conjugate for binding to the antibody. Afterseparating the support and the medium, the label activity of the supportor the medium is determined by conventional techniques and is related tothe amount of analyte in the sample.

A typical non-competitive sandwich assay is an assay disclosed in David,et al., U.S. Pat. No. 4,486,530, column 8, line 6 to column 15, line 63,incorporated herein by reference. In this method, an immune sandwichcomplex is formed in an assay medium. The complex comprises the analyte,a first antibody (monoclonal or polyclonal) that binds to the analyteand a second antibody that binds to the analyte or a complex of theanalyte and the first antibody. Subsequently, the immune sandwichcomplex is detected and is related to the amount of analyte in thesample. The immune sandwich complex is detected by virtue of thepresence in the complex of a label wherein either or both the firstantibody and the second antibody contains labels or substituents capableof combining with labels.

Sandwich assays find use for the most part in the detection of antigenand receptor analytes. In the assay the analyte is bound by twoantibodies specific for the analyte and, thus, the assay is alsoreferred to as the two-site immunometric assay. In one approach a firstincubation of unlabeled antibody coupled to a support, otherwise knownas the insoluble antibody, is contacted with a medium containing asample suspected of containing the analyte. After a wash and separationstep, the support is contacted with a medium containing the secondantibody, which generally contains a label, for a second incubationperiod. The support is again washed and separated from the medium andeither the medium or the support is examined for the presence of label.The presence and amount of label is related to the presence or amount ofthe analyte. For a more detailed discussion of this approach see U.S.Pat. Nos. Re 29,169 and 4,474,878, the relevant disclosures of which areincorporated herein by reference.

In a variation of the above sandwich assay the sample in a suitablemedium is contacted with labeled antibody for the analyte and incubatedfor a period of time. Then, the medium is contacted with a support towhich is bound a second antibody for the analyte. After an incubationperiod, the support is separated from the medium and washed to removeunbound reagents. The support or the medium is examined for the presenceof the label, which is related to the presence or amount of analyte. Fora more detailed discussion of this approach see U.S. Pat. No. 4,098,876,the relevant disclosure of which is incorporated herein by reference.

In another variation of the above, the sample, the first antibody boundto a support and the labeled antibody are combined in a medium andincubated in a single incubation step. Separation, wash steps andexamination for label are as described above. For a more detaileddiscussion of this approach see U.S. Pat. No. 4,244,940, the relevantdisclosure of which is incorporated herein by reference.

The soluble protein-polysaccharide conjugates have application to all ofthe above assays. A particular example of an assay is described below byway of illustration and not limitation. Such assay is referred to as aninduced luminescence immunoassay and is described in U.S. Pat. No.5,340,716 (Ullman, et al.) entitled “Assay Method UtilizingPhotoactivated Chemiluminescent Label” (“induced luminescence assay”),which disclosure is incorporated herein by reference. In one approachthe assay uses a particle incorporating a photosensitizer and a labelparticle incorporating a chemiluminescent compound. The label particleis conjugated to an sbp member that is capable of binding to an analyteto form a complex, or to a second sbp member to form a complex, inrelation to the presence of the analyte. If the analyte is present, thephotosensitizer and the chemiluminescent compound come into closeproximity. The photosensitizer generates singlet oxygen and activatesthe chemiluminescent compound when the two labels are in closeproximity. The activated chemiluminescent compound subsequently produceslight. The amount of light produced is related to the amount of thecomplex formed, which in turn is related to the amount of analytepresent.

by way of further illustration, a chemiluminescent particle is employed,which comprises the chemiluminescent compound associated therewith suchas by incorporation therein or attachment thereto. An sbp member thatbinds to the analyte is bound to a polysaccharide coating theseparticles. A second sbp member that binds to the analyte is part of abiotin conjugate. Streptavidin is conjugated to a second set ofparticles having a photosensitizer associated therewith. The binding ofthe streptavidin to this second set of particles (photosensitizerparticles) may or may not involve a polysaccharide on the particles. Thechemiluminescent particles are combined with a protein-polysaccharideconjugate as discussed above and this combination is mixed with a samplesuspected of containing an analyte and the photosensitizer particles.The reaction medium is incubated to allow the particles to bind to theanalyte by virtue of the binding of the sbp members to the analyte.Then, the medium is irradiated with light to excite the photosensitizer,which is capable in its excited state of activating oxygen to a singletstate. Because the chemiluminescent compound of one of the sets ofparticles is now in close proximity to the photosensitizer by virtue ofthe presence of the analyte, it is activated by the singlet oxygen andemits luminescence. The medium is then examined for the presence and/orthe amount of luminescence or light emitted, the presence thereof beingrelated to the presence of the analyte.

Another particular example of an assay to which the present solubleconjugates have application is discussed in U.S. Pat. No. 5,616,719(Davalian, et al.), which describes fluorescent oxygen channelingimmunoassays.

In general, moderate to relatively high temperatures can be employed forcarrying out an assay. The temperatures can be constant or varying andwill depend on the type of assay conducted and the reagents utilized.Incubation temperatures will normally range from about 5 to about 100°C., from about 20 to about 95° C. Temperatures during measurements willgenerally range from 5 to about 100° C., from about 20 to about 95° C.

the concentration of analyte that may be assayed will generally varyfrom about 10⁻² to about 10⁻¹⁵ M, from about 10⁻⁵ to about 10⁻¹² M.Considerations, such as whether the assay is qualitative,semiquantitative or quantitative (relative to the amount of analytepresent in the sample), the particular detection technique and theconcentration of the analyte, and optimization of the binding betweenthe specific binding materials normally determine the concentrations ofthe various reagents.

The concentrations of the various reagents in the assay medium aregenerally determined by the concentration range of interest of theanalyte. However, the final concentration of each of the reagents isnormally determined empirically to optimize the sensitivity of the assayover the range. That is, a variation in concentration of analyte that isof significance should provide an accurately measurable signaldifference.

While the concentrations of the various reagents in the assay mediumwill generally be determined by the concentration range of interest ofthe analyte to be detected, the final concentration of each of thereagents will normally be determined empirically to optimize thesensitivity of the assay over the range. That is, a variation inconcentration of the components to be detected that is of significanceshould provide an accurately measurable signal difference.

While the order of addition may be varied widely, there will be certainpreferences depending on the nature of the assay. The simplest order ofaddition is to add all the materials simultaneously. When notsimultaneous, in some embodiments the sample and the soluble compoundare mixed together prior to forming a combination with other assayreagents. In some embodiments the soluble compound and the solid supportare mixed together prior to forming a combination with other assayreagents.

Other assay reagents can be combined wholly or partially sequentially.One or more incubation steps may be involved after the reagents arecombined, generally ranging from about 1 second to about 72 hours, about10 seconds to about 24 hours, about 30 seconds to about 6 hours, about 2minutes to 1 hour.

DISCUSSION OF TERMS

Before proceeding further with the description of examples of specificembodiments of the aforementioned materials and methods, a number ofterms employed above will be defined.

Alkyl—a monovalent branched or unbranched radical derived from analiphatic hydrocarbon by removal of one H atom; includes both loweralkyl and upper alkyl.

Lower alkyl—alkyl containing from 1 to 5 carbon atoms, such as e.g.,methyl, ethyl, propyl, butyl, isopropyl, isobutyl, pentyl, isopentyl,etc.

Upper alkyl—alkyl containing more than 6 carbon atoms, usually 6 to 20carbon atoms, such as, e.g., hydroxyl, heptyl, octyl, etc.

Alkylidene—a divalent organic radical derived from an aliphatichydrocarbon, such as, for example, ethylidene, in which 2 hydrogen atomsare taken from the same carbon atom.

Aryl—an organic radical derived from an aromatic hydrocarbon by theremoval of one atom and containing one or more aromatic rings, usuallyone to four aromatic rings, such as, e.g., phenyl (from benzene),naphthyl (from naphthalene), etc., e.g., phenyl, naphthyl, phenanthryl.

Aralkyl—an organic radical having an alkyl group to which is attached anaryl group, e.g., benzyl, phenethyl, 3-phenylpropyl, 1-naphthylethyl,etc.

Alkoxy—an alkyl radical attached to the remainder of a molecule by anoxygen atom, e.g., methoxy, ethoxy, etc.

Aryloxy—an aryl radical attached to the remainder of a molecule by anoxygen atom, e.g., phenoxy, naphthoxy, etc., e.g., m-methoxyphenyl.

Aralkoxy—an aralkyl radical attached to the remainder of a molecule byan oxygen atom, e.g., benzoxy, 1-naphthylethoxy, etc.

Amine reactive functionality—a functionality reactive with an aminefunctionality, usually by virtue of nucleophilicity or basicity of theamine, such as, for example, an aldehyde, an α-keto carboxylic acid andthe like.

Alkylating agent having a functionality that reacts with an hydroxylgroup—a compound that has a functionality reactive with an hydroxylgroup, usually by virtue of nucleophilicity of the neutral or ionizedhydroxyl group, such as, for example, an oxiranyl radical, an alkylradical comprising a leaving group such as, for example, halide bromide,chloride, iodide); aryl sulfonates; alkyl sulfonates; aryl sulfates;alkyl sulfates; tosylates; acrylic acid derivatives such as acrylamide;vinyl sulfones; and the like.

Conjugate—a molecule comprised of two or more substructures boundtogether, generally through a linking group, to form a single structure.

Analyte—the compound or composition to be detected. The analyte can becomprised of a member of a specific binding pair (sbp) and may be aligand, which is usually monovalent (monoepitopic), usually haptenic,and is a single compound or plurality of compounds which share at leastone common epticopic or determinant site.

the monoepitopic ligand analytes will generally be from about 100 to2,000 molecular weight, more usually from 125 to 1,000 molecular weight.The analytes include drugs, metabolites, pesticides, pollutants, and thelike. Representative analytes, by way of example and not limitation,include (i) alkaloids such as morphine alkaloids, which includemorphine, codeine, heroin, dextromethorphan, their derivatives andmetabolites; cocaine alkaloids, which include cocaine and benzylecgonine, their derivatives and metabolites; ergot alkaloids, whichinclude the diethylamide of lysergic acid; steroid alkaloids; iminazoylalkaloids; quinazoline alkaloids; isoqunioline alkaloids; quinolinealkaloids, which include quinine and quinidine; diterpene alkaloids,their derivatives and metabolites; (ii) steroids, which include theestrogens, androgens, andreocortical steroids, bile acids, cardiotonicglycosides and aglycones, which includes digoxin, and digoxigenin,saponins and sapogenins, their derivatives and metabolites; steroidmimetic substances, such as diethylstilbestrol; (iii) lactams havingfrom 5 to 6 annular members, which include the barbiturates, e.g.,Phenobarbital and secobarbital, diphenylhydantoin, primidone,ethosuximide, and their metabolites; (iv) aminoalkylbenzenes, with alkylof from 2 to 3 carbon atoms, which include the amphetamines;catecholamines, which include ephidrine, L-dopa, epinephrine; narceine;papaverine; and metabolites of the above; (v) benzheterocyclics whichinclude oxazepam, chlorpromazine, tegretol, their derivatives andmetabolites, the heterocyclic rings being azepines, diazepines andphenothiazines; (vi) purines, which includes theophylline, caffeine,their metabolites and derivatives; (vii) drugs derived from marijuana,which include cannabinol and tetrahydrocannabinol; (viii) hormones suchas thyroxine, coritsol, triiodothyronine, testosterone, estradiol,estrone, progesterone, polypeptides such as angiotensin, LHRH, andimmunosuppressants such as cyclosporin, FK506, mycophenolic acid (MPA),and so forth; (ix) vitamins such as A, B, e.g. B12, C, D, E and K, folicacid, thiamine; (x) prostaglandins, which differ by the degree and sitesof hydroxylation and unsaturation; (xi) tricyclic antidepressants, whichinclude imipramine, dismethylimipramine, amitriptyline, nortriptyline,protriptyline, trimipramine, chlomipramine, doxepine, anddesmethyldoxepin; (xii) anti-neoplastics, which include methotrexate;(xiii) antibiotics, which include penicillin, chloromycetin,actinomycetin, tetracycline, terramycin, the metabolites andderivatives; (xiv) nucleosides and nucleotides, which include ATP, NAD,FMN, adenosine, guanosine, thymidine, and cytidine with theirappropriate sugar and phosphate substituents; (xv) miscellaneousindividual drugs which include methadone, meprobamate, serotonin,meperidine, lidocaine, procainamide, acetylprocainamide, propanolol,griseofulvin, valproic acid, butyrophenones, antihistamines,chloramphenicol, anticholinergic drugs, such as atropine, theirmetabolites and derivatives; (xvi) metabolites related to diseasedstates include spermine, galactose, phenylpyruvic acid, and porphyrinType 1; (xvii) aminoglycosides, such as gentamicin, kanamicin,tobramycin, and amikacin; and (xviii) pesticides such as polyhalogenatedbiphenyls, phosphate esters, thiophosphates, carbamates, polyhalogenatedsulfenamides, their metabolites and derivatives.

Polyvalent analytes are normally poly(amino acids), i.e., polypeptidesand proteins, polysaccharides, nucleic acids, and combinations thereof.Such combinations include components of bacteria, viruses, chromosomes,genes, mitochondria, nuclei, cell membranes and the like. For the mostpart, the polyepitopic ligand analytes will have a molecular weight ofat least about 5,000 more usually at least about 10,000. In thepoly(amino acid) category, the poly(amino acids) of interest willgenerally be from about 5,000 to 5,000,000 molecular weight, moreusually from about 20,000 to 1,000,000 molecular weight; among thehormones of interest, the molecular weights will usually range fromabout 5,000 to 60,000 molecular weight.

A wide variety of proteins may be considered as to the family ofproteins having similar structural features, proteins having particularbiological functions, proteins related to specific microorganisms,particularly disease causing microorganisms, etc. Such proteins include,for example, immunoglobulins, cytokines, enzymes, hormones, cancerantigens, nutritional markers, tissue specific antigens, etc. Suchproteins include, by way of illustration and not limitation, protamines,histones, albumins, globulins, scleroproteins, phosphorproteins,mucoproteins, chromoproteins, lipoproteins, nucleoproteins,glycoproteins, T-cell receptors, proteoglycans, HLA, unclassifiedproteins, e.g., somatotropin, prolactin, insulin, pepsin, proteins foundin human plasma, blood clotting factors, protein hormones such as, e.g.,follicle-stimulating hormone, luteinizing hormone, luteotropin,prolactin, chorionic gonadotropin, tissue hormones, cytokines, cancerantigens such as, e.g., PSA, CEA, a-fetoprotein, acid phosphatase,CA19.9 and CA125, tissue specific antigens, such as, e.g., alkalinephosphatase, myoglobin, CPK-MB and calcitonin, and peptide hormones.Other polymeric materials of interest are mucopolysaccharides andpolysaccharides.

For receptor analytes, the molecular weights will generally range fromabout 10,000 to about 2×10⁸, more usually from about 10,000 to about10⁶. For immunoglobulins, IgA, IgG, IgE and IgM, the molecular weightswill generally vary from about 160,000 to about 10⁶. Enzymes willnormally range from about 10,000 to about 1,000,000 in molecular weight.Natural receptors vary widely, generally being at least about 25,000molecular weight and may be about 10⁸ or higher molecular weight,including such materials as avidin, DNA, RNA, thyroxine bindingglobulin, thyroxine binding prealbumin, transcortin, etc.

The term analyte further includes oligonucleotide and polynucleotideanalytes such as m-RNA, r-RNA, t-RNA, DNA, DNA-RNA duplexes, etc.

The analyte may be a molecule found directly in a sample such asbiological tissue, including body fluids, from a host. The sample can beexamined directly or may be pretreated to render the analyte morereadily detectable by removing unwanted materials. The sample may bepretreated to separate or lyse cells; precipitate, hydrolyse or denatureproteins; hydrolyze lipids; solubilize the analyte; or the like. Suchpretreatment may include, without limitation: centrifugation; treatmentof the sample with an organic solvent, for example, an alcohol, such asmethanol; and treatment with detergents. The sample can be prepared inany convenient medium that does not interfere with an assay. An aqueousmedium is preferred.

The analyte of interest may be determined by detecting an agentprobative of the analyte of interest such as a specific binding pairmember complementary to the analyte of interest, whose presence will bedetected only when the analyte of interest is present in a sample. Thus,the agent probative of the analyte becomes the analyte that is detectedin an assay.

The biological tissue includes excised tissue from an organ or otherbody part of a host and body fluids, for example, urine, whole blood,plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid,tears, mucus, and the like. IN many instances, the sample is plasma orserum.

Polynucleotide—a compound or composition which is a polymeric nucleotidehaving in the natural state about 50 to 500,000 or more nucleotides andhaving in the isolated state about 15 to 50,000 or more nucleotides,usually about 15 to 20,000 nucleotides, more frequently 15 to 10,000nucleotides. Polynucleotide includes nucleic acids from any source inpurified or unpurified form, naturally occurring or syntheticallyproduced, including DNA (dsDNA and ssDNA) and RNA, usually DNA, and maybe t-RNA, m-RNA, r-RNA, mitochondrial DNA and RNA, chloroplast DNA andRNA, DNA-RNA hybrids, or mixtures thereof, genes, chromosomes, plasmids,the genomes of biological material such as microorganisms, e.g.,bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals,humans, and fragments thereof, and the like.

Ligand—any organic compound for which a receptor naturally exists or canbe prepared.

Hapten—a compound capable of binding specifically to correspondingantibodies, but does not itself act as an immunogen (or antigen) forpreparation of the antibodies. Antibodies which recognize a hapten canbe prepared against compounds comprised of the hapten linked to animmunogenic (or antigenic) carrier. Haptens are a subset of ligands.

Ligand analog—a modified ligand, an organic radical or analyte analog,usually of a molecular weight greater than 100, which can complete withthe analogous ligand for a receptor, the modification providing means tojoin a ligand analog to another molecule. The ligand analog will usuallydiffer from the ligand by more than replacement of a hydrogen with abond which links the ligand analog to a hub or label, but need not. Theligand analog can bind to the receptor in a manner similar to theligand. The analog could be, for example, an antibody directed againstthe idiotype of an antibody to the ligand.

Receptor (“antiligand”)—any compound or composition capable ofrecognizing a particular spatial and polar organization of a molecule,e.g., epitopic or determinant site. Illustrative receptors includenaturally occurring receptors, e.g., thyroxine binding globulin,antibodies, enzymes, Fab fragments, lectins, nucleic acids, protein A,complement component C1q, and the like.

Antibody—an immunoglobulin that specifically binds to and is therebydefined as complementary with a particular spatial and polarorganization of another molecule. The antibody can be monoclonal orpolyclonal and can be prepared by techniques that are well known in theart such as immunization of a host and collection of sera (polyclonal)or by preparing continuous hybrid cell lines and collecting the secretedprotein (monoclonal), or by cloning and expressing nucleotide sequencesor mutagenized versions thereof coding at least for the amino acidsequences required for specific binding of natural antibodies.Antibodies may include a complete immunoglobulin or fragment thereof,which immunoglobulins include the various classes and isotypes, such asIgA, IgD, IgE, IgG1, IgG2a, IgG2b and IgG3, IgM, etc. Fragments thereofmay include Fab, Fv and F(ab′)₂, Fab′, and the like. In addition,aggregates polymers, and conjugates of immunoglobulins or theirfragments can be sued where appropriate so long as binding affinity fora particular molecule is maintained.

Substituted—means that a hydrogen atom of a molecule has been replacedby another atom, which may be a single atom such as a halogen, etc., orpart of a group of atoms forming a functionality as described above.Such substituent may be a group or functionality impartinghydrophilicity. As discussed above, hydrophilicity may be achieved by afunctional group having one or more atoms such as oxygen nitrogen,sulfur, phosphorus, and so forth; such groups include sulfonate,sulfate, phosphate, amidine, phosphonate, carboxylate, hydroxylparticularly polyols, amine ether, amide, and the like.

Signal producing system (“sps”)—one or more components, at least onecomponent being a detectable label, which generate a detectable signalthat relates to the amount of bound and/or unbound label, i.e. theamount of label bound or not bound to the compound being detected. Thelabel is any molecule that produces or can be induced to produce asignal, and may be, for example, a fluorescer, radio-label, enzyme,chemiluminescer or photosensitizer. Thus, the signal is detected and/ormeasured by detecting enzyme activity, luminescence, light absorbance orradioactivity as the case may be.

Suitable labels include, by way of illustration and not limitation,enzymes such as alkaline phosphatase, glucose-6-phosphate dehydrogenase(“G6PDH”) and horseradish peroxidase; ribozyme; a substrate for areplicase such as QB replicase; promoters; dyes; fluorescers, such asfluorescein, isothiocyanate, rhodamine compounds, phycoerythrin,phycocyanin, allophycocyanin, or-phthaldehyde, and fluorescamine;chemilluminescers such as isoluminol; sensitizers; coenzymes; enzymesubstrates; radiolabels such as ¹²⁵I, ¹⁸¹ ^(I,) ¹⁴C, ³H, ⁵⁷Co and ⁷⁵Se;particles such as latex or carbon particles; metal sol; crystallite;liposomes; cells, etc., which may be further labeled with a dye,catalyst or other detectable group. Suitable enzymes and coenzymes aredisclosed in Litman, et al., U.S. Pat. No. 4,275,149, columns 19-28, andBoguslaski, et al., U.S. Pat. No. 4,318,980, columns 10-14; suitablefluorescers and chemiluminescers are disclosed in Litman, et al., U.S.Pat. No. 4,275,149, at columns 30 and 31; which are incorporated hereinby reference.

There are numerous methods by which the label can produce a signaldetectable by external means, desirably by visual examination, forexample, by electromagnetic radiation, heat, and chemical reagents. Thelabel or other sps members can also be bound to an sbp member, anothermolecule or to a support.

Labels include groups detectable by means of electromagnetic radiationor by electrochemical detecting including dyes, fluorescers,chemiluminescers, and radioactive isotopes.

The label can directly produce a signal and, therefore, additionalcomponents are not required to produce a signal. Numerous organicmolecules, for example fluorescers, are able to absorb ultraviolet andvisible light, where the light absorption transfers energy to thesemolecules and elevates them to an excited energy state. This absorbedenergy is then dissipated by emission of light at a second wavelength.Other labels that directly produce a signal include radioactive isotopesand dyes.

Alternately, the label may need other components to produce a signal,and the signal producing system would then include all the componentsrequired to produce a measurable signal, which may include substrates,coenzymes, enhancers, additional enzymes, substances that react withenzymic products, catalysts, activators, cofactors, inhibitors,scavengers, metal ions, and a specific binding substance required forbinding of signal generating substances. A detailed discussion ofsuitable signal producing systems can be found in Ullman, et al., U.S.Pat. No. 4,185,243, columns 11-13, incorporated herein by reference.

The label and/or other sps member may be bound to an sbp member or to asupport. For example, the label can be bound covalently to an sbp membersuch as, for example, an antibody; a receptor for an antibody, areceptor that is capable of binding to a small molecule conjugated to anantibody, or a ligand analog. Bonding of the label to the sbp member maybe accomplished by chemical reactions that result in replacing ahydrogen atom of the label with a bond to the sbp member or may includea linking group between the label and the sbp member. Other sps membersmay also be bound covalently to sbp members. For example, two spsmembers such as a fluorescer and quencher can each be bound to adifferent antibody that forms a specific complex with the analyte.Formation of the complex brings the fluorescer and quencher in closeproximity, thus permitting the quencher to interact with the fluorescerto produce a signal. Methods of conjugation are well known in the art.See, for example, Rubenstein, et al., U.S. Pat. No. 3,817,837,incorporated herein by reference.

Assay—method for the determination of the presence or amount of ananalyte.

Measuring the amount of an analyte—quantitative, semiquantitative, andqualitative methods as well as all other methods for determining ananalyte are considered to be methods of measuring the amount of ananalyte. For example, a method, which merely detects the presence orabsence of an analyte in a sample suspected of containing the analyte,is considered to be included within the scope of the present invention.The terms “detecting” and “determining,” as well as other commonsynonyms for measuring, are contemplated within the scope of the presentinvention.

Ancillary Materials—Various ancillary materials will frequently beemployed in the assay in accordance with the present invention. Forexample, buffers will normally be present in the assay medium, as wellas stabilizers for the assay medium and the assay components.Frequently, in addition to these additives, proteins may be included,such as albumins; organic solvents such as formamide; quaternaryammonium salts; polyanions such as dextran sulfate; surfactants,particularly non-ionic surfactants; binding enhancers, e.g.,polyalkylene glycols; or the like.

Wholly or partially sequentially—when various agents are combined otherthan concomitantly (simultaneously), one or more may be combined withone or more of the remaining agents to form a subcombination.

The invention is demonstrated further by the following illustrativeexamples.

EXAMPLES

Parts and percentages herein are by weight unless otherwise indicated.Temperatures are in degrees Centigrade (° C.).

Abbreviations:

-   EDTA—ethylenediamine tetraacetic acid-   CTNI—Tropinin C-   HAMA—human antimouse antibody-   BSA—bovine serum albumin-   MES—2-morpholinoethanesulfonic acid-   PBS—phosphate buffered saline at physiological pH and ionic strength-   CMO—carboxymethoxyamine-   CV—coefficient of variation-   HEPES buffer—-   kDa—kilodalton-   NSB—non-specific binding    Materials:    Chemicals:

Unless noted otherwise, all chemicals were purchased from theSigma-Aldrich Company (St. Louis, Mo.). HAMA blockers were purchasedfrom Roche Diagnostics Corporation (Roche Applied Science, Indianapolis,Ind.) and from Scantibodies Laboratory, Inc. 9336 Abraham Way Santee,Calif. 92071 USA. The grade of BSA used for conjugation reactions isknown as “fatty acid free” BSA.

Test Samples:

Samples from a local blood bank were screened to determine if theyproduced a response with the troponin assay. Any donor sample thatproduced a positive result with the troponin test was assumed to be afalse positive. This was confirmed by testing all samples that gavepositive responses with at least one commercially available referencemethod. For the results reported here, the test results were confirmedusing the Dade Behring DIMENSION RxI® troponin (CTNI) test. The falsepositive samples were further screened for known causes of falsepositivity. The primary root cause of false positive results is humanantibodies that bind mouse antibodies, an interference known as “HAMA”(Human Anti-Mouse Antibodies). The screening process used to determineif samples have HAMA interference consists of adding known HAMA binders(also known as blocking agents) that are available commercially fromRoche and Scantibodies. If a sample that gives a positive responsebecomes normal when HAMA binders are added to the sample, the sample isassumed to be a false positive due to HAMA. Some samples were notcorrected by the addition of HAMA binders. These were used in thetesting described in the following examples.

Test Assays:

An assay for CTNI, described in “Quantitation of Cardiac Markers byLOCI™ Technology”, R. Bauer, et al., (Clinical Chemistry 2004; 50(6supplement): A5) was used for evaluation of the candidate blockercompounds. The reagents for doing this assay consist of an antibodycoated acceptor latex (acceptor bead) that emits light when contacted bysinglet oxygen, a biotinylated antibody, and a streptavidin coated donorlatex that produces singlet oxygen when illuminated by light ofwavelengths that are absorbed by a photosensitizer dye dissolved in thelatex particles. The streptavidin of the donor latex was bound to thelatex particles through a spacer of dextran with aldehyde linkinggroups. In the case of the acceptor beads, the antibody was connected tothe particles through a linking group or spacer that results from acombination of aminodextran and dextranaldehyde. For both latexreagents, the excess aldehyde groups remaining after linkage of theproteins are reacted with carboxymethoxyamine to quench the aldehydes.

These reagents are packaged in FLEX® containers that serve as reservoirsfor the VISTA™ automated clinical analyzer that is described in“Development and Initial Performance of a new High-Volume Multi-Detectoranalyzer: the DIMENSION VISTA™ Integrated System”, T. Evers, et al.(Clinical Chemistry 2004, 50(6supplement)) A31. The test kits and theanalyzer are available from Dade Behring Inc., Newark, Del., USA.Candidate blocking reagents (soluble protein-polysaccharide conjugates(preformed or formed in situ) that reduce or eliminate interference fromsample components) were tested by adding them (or a precursor such as,e.g., dextran aldehyde) to the biotinylated antibody reagent inprototype FLEX® containers or in some cases directly to the sample.FLEX® containers are from Dade Behring Inc.

Each test result shown in the tables below is the average of four testresults. In general, the precision of the measurements was <2% CV forcalibrators and for measurements of discrepant samples in those caseswhere effective blockers were used. The testing was done on differentdays with different instruments, so many control tests were needed toenable comparison of different sets of data.

Example 1 Synthesis of Soluble Protein-Polysaccharide Conjugate

Part A: Synthesis of Dextranaldehyde

One hundred grams (100 g) of 100-200 kDa dextran was added slowly withstirring to 400 mL of deionized water containing 0.5 g of EDTA in a 1 Lround bottom flask equipped with a nitrogen purge. To this mixture, 40 gof NaOH was added followed by 15 mL of 2-(4-chlorobutyl)-1,3-dioxolane.The mixture was heated to 90° and held at that temperature with stirringfor 24 hours. At this time, 250 mL of water was added, and the mixturewas cooled to room temperature using an ice bath. The pH was thenadjusted to 6.0-6.5 by slowly adding 12N HCl with stirring. The mixturewas then purified by diafiltration using a hollow fiber diafiltrationcartridge having a molecular weight cutoff of 10,000 Daltons. A total of60 L of deionized water was exchanged in the process. The intermediatedioxolane was removed from the diafiltration apparatus, and the volumewas adjusted to 1200 mL.

toluenesulfonic acid (68.5 g) was added to the dioxolane solution, andthe pH was adjusted to 1.8 with pyridine. The mixture was allowed tostand for 16 hours at room temperature, and then the pH was adjusted to6.0 with 1N NaOH. It was purified against using a hollow fiber 10,000Dalton cutoff diafiltration cartridge, by exchange of 125 L of water.

After removal of the product from the diafiltration system, itsconcentration was adjusted to approximately 50 mg/mL, and then bufferedto pH 7.0 by addition of 0.69 mg/mL of monobasic sodium phosphatemonohydrate and 0.71 mg/mL of anhydrous dibasic sodium phosphate. Thesolids content was determined to be 45.9 mg/mL.

The same procedure was used with 500 kDa dextran to make a highermolecular weight version of dextranaldehyde.

Part B: Synthesis of Dextranaldehyde/Protein Conjugates

The same general synthesis scheme as described in Part A was used for aseries of different conjugates that differed in the ratio ofdextranaldehyde to protein, the molecular weight of the dextranaldehyde,and the type of protein. The nomenclature used to identify thecomposition of the candidate soluble conjugates is:xxmwtDexal-proteinyymg/100 mg of dextranaldehyde. For example100-200-dexal-BSA-30 would be a product made with dextranaldehydeprepared from 100-200 kDa dextran that had been conjugated with BSA at aratio of 100 parts dextranaldehyde to 30 parts BSA.

Preparation of 100-200dexal-BSA30: 1.5 mL of a solution of 20 mg/mL BSAin pH 6.0, 50 mM MES buffer was added with stirring to 2.18 mL of adextranaldehyde solution containing 100 mg. After the addition wascomplete, 0.3 mL of a 100 mg/mL solution of sodium cyanoborohydride wasadded with stirring. The mixture was put in a shaker air bath and heldat 37° C. for 18 hours. It was then put in a 6000-8000 molecular weightcutoff dialysis bag and dialyzed against 1 L of deionized water, whichwas exchanged three times. The final, fourth exchange was against 1 L ofpH 6.0 50 mM MES buffer.

Part C: Synthesis of Carboxymethyl Dextranaldehyde Oxime

One (1) mL of a 1M solution of carboxymethoxylamine hemihydrochloridewas added to a solution of 100 mg of 100-200 kDa dextranaldehyde in 2.18mL, and the mixture was incubated at 37° C. for 2 hours. It was then putin a 6000-8000 molecular weight cutoff dialysis bag and dialyzed against1L of deionized water, which was exchanged three times. The durationbetween exchanges was 3-4 hours. The final, fourth exchange was against1L of pH 6.0 50 mM MES buffer.

Part D: Synthesis of Dextranaldehyde Modified with Aliphatic Amines

The process for preparing dextranaldehyde modified by different amineswas essentially the same, using different amines, at differentconcentrations. Table 1 below lists the quantities and the amines thatwere used. TABLE 1 Quantity μmoles Amine MW used used Ethanolamine 6122.5 mg 369 Methyl amine 31 33 μL 369

The amine was added with stirring to 100 mg of dextranaldehyde in 2.18mL, followed by 0.3 mL of a stock solution of 100 mg/mL in water and themixture was incubated for two hours at 37° C. It was then put in a6000-8000 molecular weight cutoff dialysis bag and dialyzed against 1 Lof deionized water, which was exchanged three times. The durationbetween exchanges was 3-4 hours. The final, fourth exchange was against1 L of pH 6.0 50 mM MES buffer.

Example 2 Immunoassay Testing

Part A: comparative Blocking Activity of Dextran and Dextranaldehyde/BSAConjugate Formed in situ in an Assay for Troponin

Dextranaldehyde reacts with proteins to form Schiff's bases between thealdehyde functionality and the lysine amino groups of proteins therebyproducing a conjugate. This reaction was accomplished by adding 5 mg/mL500 kDa dextranaldehyde to the biotinylated antibody reagent of the CTNIFLEX® container, which contains 50 mg/mL of BSA in a pH 7.2 HEPES bufferwith 1 mg/mL 100-200 KDa dextran. The effect of the addition on theresponse of the assay to both calibrators (Cal 0 representing 0 ng/ml oftroponin and Cal 8.3 representing 8.3 ng/ml troponin) and discrepantfalse positive samples (identified as NSB 1-29) is seen in Table 2below. TABLE 2 No Dextranaldehyde counts Dextranaldehyde Added Meanratio, counts ratio, Samples: counts NSB/Cal0 Mean counts NSB/Cal0 Cal 0ng/mL 7,978 N/A 7857 N/A Cal 8.3 ng/mL 1,026,400 N/A 989444 N/A NSB 1767,083 96.15 10607 1.34 NSB 3 87,991 11.03 10049 1.28 NSB 7 44,076 5.529247 1.18 NSB 15 30,810 3.86 7920 1.01 NSB 16 20,211 2.53 7666 0.98 NSB17 93,031 11.66 7715 0.98 NSB 18 14,232 1.78 7533 0.96 NSB 20 61,7827.74 8589 1.09 NSB 21 319,324 40.03 8284 1.05 NSB 23 119,889 15.03 77710.99 NSB 26 24,607 3.08 8081 1.03 NSB 27 24,662 3.09 7431 0.95 NSB 2919,800 2.48 7566 0.96

The BSA conjugate formed in situ had the effect of nearly bringing thefalsely elevated results to the same level as the zero calibrator (“Cal0 ng/mL”). Only samples NSB 1, 3, 7, and 20 remained significantlyelevated above the background. By comparison, the data show thatunmodified dextran was relatively ineffective for blocking thenonspecific binding.

Table 3 below shows the effect of adding 20 mg/mL of two differentmolecular weight grades of dextran using the same protocol as above:TABLE 3 counts ratio, Sample Mean NSB/Cal0 20 mg/mL of Dextran 500 Cal 06,237 N/A Cal 6 1,273,769 N/A NSB 1 13,082 1.59 NSB 3 11,440 1.39 NSB 78,691 1.06 20 mg/mL of Dextran 100-200 Cal 0 7,392 N/A Cal 8 953,703 N/ANSB 1 18,736 2.53 NSB 3 9,613 1.30 NSB 7 8,006 1.08

In this example, the dextran was added to both the biotinylated antibodyreagent and the acceptor bead reagent and Cal 0 represented a calibratorsolution having 0 ng/ml of troponin and Cal 8 represented a calibratorsolution having 8.3 ng/ml troponin. There was some improvement comparedto the case where no additional dextran was added, but the improvementseen was significantly less than with the soluble protein-polysaccharideconjugate, i.e., dextranaldehyde/BSA Schiff's base conjugate, ofembodiments of the invention.

Part B: Testing of Dextranaldehyde/Protein Conjugates

As will be seen in examples, below, results with the in situ conjugate,which was used as a control for other experiments, were variable fromrun-to-run. This could be due to the fact that the Schiff's base thatforms is unstable and spontaneously dissociates and re-associates. Forin situ formation of the soluble conjugate, the dextran aldehyde shouldeither be added to the sample before the first assay reagent or to thereagent that is first mixed with the patient sample. In the case wherethe in situ conjugate is formed in the reagent, the reagent shouldcontain a protein such as BSA or the like at a concentration of at least0.5 mg/mL, at least 1 mg/mL, at least 1.5 mg/mL, at least 2.0 mg/mL, andso forth.

In the first experiment, the candidate blocker materials were added tothe calibrators and the NSB-1 discrepant sample, and the mixture washeld for a half an hour before testing was done. The candidate blockerswere added to give a concentration of 1 mg/mL by adding 5 μL of a 20mg/mL stock to 0.1 mL of sample. The reagent for the control conditionidentified as “PBS control” was prepared by diluting the biotinylatedantibody reagent to the same extent as the tests with phosphate bufferedsaline (10 mM sodium phosphate, 120 mM sodium chloride, 7.2 mM potassiumchloride, pH 7.2). The results are shown below in Table 4. TABLE 4 TestResult Counts % Additive Cal 0 Cal 8 NSB 1 supression* PBS as control8,916 979,811 999,031  0.0% 500-Dextran aldehyde 8,809 864,795 9,95099.88%  100-200-Dexal-BSA-10 8,389 954,766 26,160 98.2%100-200-Dexal-BSA-30 8,460 969,563 11,242 99.7%*% supression = 1 − (test NSB 1 − test cal 0)/(control NSB 1 − Cal 0)

while most of the non-specific elevation was eliminated with the threeblockers above, there was still a small false positive signal with theNSB-1 sample. The above results may be acceptable for many assays;however, a troponin assay has higher demands for interference controlthan many other assays.

Additional conjugates were made using a higher level of BSA in thesynthesis, different proteins and also higher molecular weightdextranaldehyde. The additives were put into the biotinylated antibodyreagent at a concentration of 5 mg/mL. The results of testing of theseconjugates are summarized in Table 5 below: TABLE 5 Test Result Counts %Run 1 Additive Cal 0 Cal 8 NSB 1 supression* PBS (control) 7,232 733,189889,128  0.0% 100-200-Dexal-BSA-50, first lot 6,578 743,213 7,005 99.95%100-200-Dexal-BSA-50, 7,136 807,327 7,134 100.00%  second lot100-200-Dexal-BSA-100 7,320 823,386 7,544 99.97% 100-200-Dexal-MurineIgG-20 6,619 794,745 7,909 99.85% % Run 2 Additive Cal 0 Cal 8 NSB 1supression* PBS (control) 7,177 707,027 823,326  0.00%100-200-Dexal-ovalbumin-100 6,370 734,218 39,569 95.93%100-200-Dexal-ovalbumin-50 6,573 749,661 12,630 99.26%*% supression = 1 − (test NSB 1 − test cal 0)/(control NSB 1 − Cal 0)

While these data show in this experiment that the most effective blockerof the series of protein conjugates was the one based upon BSA, otherproteins also resulted in conjugates that exhibited effective blockingof interference. In addition, in this experiment, performance of theconjugates appears to reach a plateau when the ratio of dextranaldehydeto BSA in the synthesis is in the range of 2:1 to 1:1. It should benoted that the above ratio range is for dextranaldehyde and BSA. Ingeneral, the ratio will depend on the nature of the polysaccharide suchas, e.g., the chemical composition, molecular weight, etc., and on thenature of the protein such as, e.g., chemical composition, molecularweight, etc.

Part C: Blocking with Small Molecule/Dextran Derivatives:

A series of derivatives were tested to compare the blocking activity ofdextran and functionalized dextran to the soluble dextran-proteinconjugates of embodiments of the present invention.

Testing of low molecular weight amine derivatives of dextranaldehyde wasdone by adding these to the samples at a concentration of 1 mg/mL. Inthe case of the dextranaldehyde additive, the mixture was allowed tostand for half an hour before testing to give time for it to react withthe serum proteins of the samples. The comparative assay results areshown in Table 6 below: TABLE 6 Test Result Counts Additive Cal 0 Cal 8NSB 1 % supression* PBS as control 8,916 979,811 999,031  0.0%500-Dextran aldehyde 8,809 864,795 9,950 99.88%  100-200-Dexal- 9,018971,960 216,201 79.1% ethanolamine 100-200-Dexal- 8,690 950,346 206,47180.0% methylamine*% supression = 1 − (test NSB 1 − test cal 0)/(control NSB 1 − Cal 0)

The blocking ability of the dextranaldehyde-alkyl amine derivatives wassignificantly less than the blocking ability of the reaction product ofdextranaldehyde with serum proteins of the sample.

The following experiment compared the blocking ability of the reactionproduct of dextranaldehyde with BSA proteins in the sample to theblocking ability of the carboxymethyloxime (CMO) derivative of dexal,which cannot react with serum proteins. In this case, the test additiveswere added to the biotinylated antibody reagent at a concentration of 5mg/mL. The test results are shown in Table 7 below: TABLE 7 Test ResultCounts Additive Cal 0 Cal 8 NSB 1 % supression* PBS (control) 8,2981,011,502 1,049,243 0.0% 500 Kdal 7,857 989,444 10,507 99.7%Dextranaldehyde 100-200-Dexal-CMO 8,384 1,052,110 1,026,872 2.2%*% supression = 1 − (test NSB 1 − test cal 0)/(control NSB 1 − Cal 0)

The Schiff's base reaction product of dextranaldehyde and BSA issignificantly more effective at blocking the interference than is thecarboxymethyloxime derivative of dexal.

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it will be readily apparent to those of ordinary skill inthe art in light of the teachings of this invention that certain changesand modifications may be made thereto without departing from the spiritor scope of the appended claims. Furthermore, the foregoing description,for purposes of explanation, used specific nomenclature to provide athorough understanding of the invention. However, it will be apparent toone skilled in the art that the specific details are not required inorder to practice the invention. Thus, the foregoing descriptions ofspecific embodiments of the present invention are presented for purposesof illustration and description; they are not intended to be exhaustiveor to limit the invention to the precise forms disclosed. Manymodifications and variations are possible in view of the aboveteachings. The embodiments were chosen and described in order to explainthe principles of the invention and its practical applications and tothereby enable others skilled in the art to utilize the invention.

1-13. (canceled)
 14. A method for reducing non-specific binding in abinding assay for the determination of an analyte in a sample whereinone of said reagents for conducting said binding assay comprises a solidsupport comprising a second polysaccharide, said method comprisingincluding in an assay medium for conducting said binding assay a solublecompound comprising a protein linked to a first polysaccharide.
 15. Amethod according to claim 14 wherein said soluble compound has a neutralcharge or a negative charge.
 16. A method according to claim 14 whereinthe affinity binding behavior of said soluble compound is greater thanthe affinity binding behavior of said second polysaccharide on saidsupport.
 17. A method according to claim 14 wherein said sample and saidsoluble compound are mixed together prior to forming said combination.18. A method according to claim 14 wherein said soluble compound andsaid solid support are mixed together prior to forming said combination.19. A method according to claim 14 wherein said first polysaccharide isdextran or a dextran derivative.
 20. A method according to claim 14wherein said protein is a serum protein.
 21. A method according to claim20 wherein said serum protein is an albumin or a gamma globulin.
 22. Amethod according to claim 14 wherein said solid support comprisesparticles.
 23. A method according to claim 14 wherein said secondpolysaccharide is linked to said solid support and a member of aspecific binding pair is linked to said second polysaccharide.
 24. Amethod according to claim 14 wherein said first polysaccharide and saidsecond polysaccharide are the same.
 25. A method according to claim 14wherein said first polysaccharide and said second polysaccharidecomprise the same monosaccharide polymer subunit but differ by molecularweight.
 26. A method according to claim 25 wherein the molecular weightof said first polysaccharide is greater than the molecular weight ofsaid second polysaccharide. 27-32. (canceled)